4978
vs
C
CANF
4978
Over the past 12 months, ReproCell Inc has significantly outperformed CANF, delivering a return of +30% compared to the CANF's 91% drop.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
4978
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Multiples-Based Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
ReproCell Inc
TSE:4978
|
179
JPY
|
|||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
505
ILS
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
4978, CANF
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
|
ReproCell Inc
Revenue
|
|||||||||||
|
C
|
Can Fite Biopharma Ltd
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
4978, CANF
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
|
ReproCell Inc
TSE:4978
|
|||||||||
|
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
|||||||||
Compare company's free cash flow with its competitors.
Gross Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Net Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROIC
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
ROCE
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
ReproCell Inc | ||||
|
C
|
Can Fite Biopharma Ltd | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
4978, CANF
Performance By Year
4978, CANF
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| FR |
|
Pharnext SCA
OTC:PNEXF
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
|
| US |
S
|
Seagen Inc
F:SGT
|
